share_log

Smart for Life CEO Issues Year-End Letter to Shareholders

Smart for Life CEO Issues Year-End Letter to Shareholders

Smart for Life 首席执行官致股东年终
GlobeNewswire ·  2023/01/12 09:06

2022 Marked Transformative Year for Smart for Life; Built a Solid Foundation Through Acquisitions and Anticipates Significant Growth in 2023

2022年标志着Smart for Life的变革之年;通过收购奠定了坚实的基础,并预计2023年将实现显著增长

MIAMI, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) ("Smart for Life" or the "Company"), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today provided the following letter to shareholders from the Company's CEO, Darren Minton:

迈阿密,2023年1月12日(环球通讯社)--智能生活公司(纳斯达克代码:SMFL)(“生活智能”或“公司”)作为全球健康与健康行业营销和营养食品及补充剂制造领域的高增长全球领导者,今天,该公司首席执行官达伦·明顿向股东提供了以下信件:

"2022 was truly a transformative year for Smart for life and as we look toward a promising year ahead, I am proud to reflect on all that we have achieved. In the beginning of 2022, we completed our Initial Public Offering and raised gross proceeds of $14.4 million. We have now completed five major acquisitions since our formation which not only validates our ability to acquire accretive businesses at attractive multiples but also our ability to successfully integrate these companies within our organization. Although 2022 has certainly been a tumultuous year in the capital markets, our proactive "Buy and Build" strategy is working—we are currently generating pro forma revenues in excess of $30 million and anticipate expanding to over $100 million in annualized revenues in the next twelve months based on anticipated acquisitions and organic growth. In addition, as we have publicly announced, we have an objective of achieving $300 million in revenues within the next 36 months.

2022年对Smart来说确实是变革性的一年,当我们展望未来充满希望的一年时,我很自豪地反思我们所取得的所有成就。2022年初,我们完成了首次公开募股,筹集了1440万美元的毛收入。自我们成立以来,我们已经完成了五项重大收购,这不仅验证了我们以诱人的倍数收购增值业务的能力,也验证了我们成功将这些公司整合到我们组织内的能力。尽管2022年肯定是资本市场动荡的一年,但我们积极的“购买并构建”战略正在奏效-我们目前的预计收入超过3000万美元,并预计在未来12个月内基于预期的收购和有机增长,年化收入将扩大到1亿美元以上。此外,正如我们已经公开宣布的那样,我们的目标是在未来36个月内实现3亿美元的收入。

Through our subsidiaries, we boast a dynamic, exciting mix of brands and capabilities including Ceautamed Worldwide LLC, GSP Nutrition Inc. (which owns a license in the U.S. and Canada for the exclusive use of certain of the Sports Illustrated brands in the fields of dietary and nutritional supplements), Doctors Scientific Organica, LLC, Bonne Santé Natural Manufacturing, Inc. and Nexus Offers, Inc. Our current businesses include two state-of-the-art FDA-certified contract manufacturing facilities, spanning an aggregate of 60,000 sq. ft., along with consumer brands, digital marketing services, and licensing agreements. We offer a variety of cutting-edge formulary and manufacturing capabilities including capsules, tablets, powders, health bars, baked goods, functional foods, and other product types and delivery methods.

通过我们的子公司,我们拥有充满活力、令人兴奋的品牌和能力组合,包括Ceautame Worldwide LLC、GSP Nutrition Inc.(它在美国和加拿大拥有在饮食和营养补充剂领域独家使用某些体育画报品牌的许可证)、Doctors Science Organica,LLC、Bonne SantéNatural制造公司和Nexus Offers,Inc.。我们目前的业务包括两个最先进的FDA认证的合同制造设施,总面积达60,000平方米。以及消费品牌、数字营销服务和许可协议。我们提供各种尖端配方和制造能力,包括胶囊、片剂、粉末、健康棒、烘焙食品、功能食品和其他产品类型和交付方式。

We achieved several noteworthy milestones in 2022:

我们在2022年取得了几个值得注意的里程碑:

  • Launched new line of Greens First protein bars
  • Achieved strong revenue growth: Q3 2022 revenues increased 59.1% year-over-year to $5.4 million due to successful acquisition strategy; Q3 2022 profit margin increased to 49.1%, versus 42.6% for the same period last year
  • Initiated capital restructuring designed to increase shareholders' equity and contribute toward our continued Nasdaq listing requirements
  • Opened new corporate headquarters, consolidated operations aimed at delivering greater savings and efficiencies at scale
  • Executed Letter of Intent for strategic co-venture with Cosmos Health, Inc. (Nasdaq: COSM) to cross market products and services in their reciprocal markets
  • Announced Letter of Intent to acquire a premier eCommerce nutraceuticals company with operations in North America; acquisition is expected to add over $12 million of revenue and to be accretive to earnings
  • Formed Smart Acquisition Group, LLC to accelerate M&A activities; named Stuart Benson, JD as Managing Director
  • Completed strategic acquisition of Ceautamed Worldwide LLC owner of Greens First Brand; expected to be highly synergistic and accretive, while adding established medical distribution channels and expanding product portfolio
  • Partnered with Milk Dust for manufacturing of its proprietary products designed to support mother's breast milk production during baby formula shortage
  • Aided shipment of over 100,000 meal replacement bars to Ukraine to help those in need
  • Selected by Amazon to launch various Smart for Life products in Singapore
  • Acquired Sports Illustrated™ trademark rights as described above
  • 推出新的绿色第一蛋白质棒系列
  • 实现了强劲的收入增长:由于成功的收购战略,2022年第三季度的收入同比增长59.1%,达到540万美元;2022年第三季度的利润率从去年同期的42.6%提高到49.1%
  • 启动资本重组,旨在增加股东权益,并为我们继续满足纳斯达克上市要求做出贡献
  • 开设新的公司总部,整合运营,旨在实现更大规模的节约和效率
  • 与Cosmos Health,Inc.(纳斯达克代码:COSM)签署战略合资意向书,在各自的互惠市场交叉销售产品和服务
  • 宣布收购一家在北美开展业务的顶级电子商务营养食品公司的意向书;收购预计将增加1200多万美元的收入,并增加收益
  • 成立了智能收购集团LLC以加快并购活动;任命斯图尔特·本森JD为董事的管理
  • 完成对Ceautame Worldwide LLC的战略收购,拥有Greens First Brand;预计将实现高度协同和增值,同时增加现有的医疗分销渠道并扩大产品组合
  • 与奶粉公司合作生产其专有产品,旨在支持婴儿配方奶粉短缺期间母亲的母乳生产
  • 协助向乌克兰运送超过10万条代餐棒材,以帮助有需要的人
  • 被亚马逊选中在新加坡推出各种智能生活产品
  • 如上所述获得《体育画报》™商标权

In summary, Smart for Life represents an exciting opportunity to invest in a dynamic, innovative, proactive organization capitalizing on the fragmented yet rapidly growing nutraceutical market. We believe our proactive acquisition strategy, targeting accretive cash flow positive companies, combined with strategies to enhance organic growth, represents the best path to drive long-term value for shareholders. We are extremely well positioned to take advantage of the opportunities in front of us and are excited about the outlook for 2023 and beyond."

总而言之,Smart for Life代表着一个令人兴奋的机会,可以投资于一个充满活力、创新、积极主动的组织,利用支离破碎但快速增长的营养食品市场。我们相信,我们的主动收购战略,目标是增加现金流的积极公司,与促进有机增长的战略相结合,是为股东推动长期价值的最佳途径。我们处于非常有利的地位,可以利用摆在我们面前的机会,并对2023年及以后的前景感到兴奋。

About Smart for Life, Inc.

关于Smart for Life,Inc.

Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-six months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: .

Smart for Life,Inc.(纳斯达克代码:SMFL)从事各种营养及相关产品的开发、营销、制造、收购、运营和销售,重点是健康和健康。作为一家公开持股的全球控股公司,该公司正在执行一项先买后建战略,通过一系列增值收购创建一家垂直整合的公司,目标是在未来36个月内将收入至少为3亿美元的公司聚集在一起。为了推动增长和收益,Smart for Life正在开发专有产品,并收购其他盈利公司,包括品牌、制造和分销渠道。该公司目前经营着五家子公司,包括Doctors Science Organica、Nexus Offers、Bonne SantéNatural Manufacturing、GSP Nutrition和Ceautame Worldwide。有关Smart for Life的更多信息,请访问:。

Video regarding the Company's manufacturing facility at Bonne Santé Natural Manufacturing is available at: .

有关该公司在Bonne SantéNatural Manufacturing的制造设施的视频可在以下网址获得:

Investor material and a Fact Sheet with additional information about Smart for Life is available at: .

投资者材料和包含有关Smart for Life的更多信息的情况说明书可在以下网站获得:

Forward-Looking Statements

前瞻性陈述

This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management's beliefs, assumptions and expectations of Smart for Life's future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in "Risk Factors" included in our filings with the Securities and Exchange Commission.

本新闻稿可能包含有关我们对未来预期、计划和前景的看法的信息,这些信息构成了前瞻性陈述。所有前瞻性陈述都是基于管理层对Smart for Life未来经济表现的信念、假设和预期,并考虑到目前掌握的信息。这些陈述不是对历史事实的陈述。尽管Smart for Life相信这些前瞻性陈述中反映的预期是基于合理的假设,但它不能保证其预期将会实现。除非法律要求,否则Smart for Life不承担更新本文中包含的任何陈述(包括任何前瞻性陈述)的任何责任。不能保证Smart for Life将成功收购其收购目标。前瞻性陈述受许多因素、风险和不确定因素的影响,其中一些因素目前尚不为我们所知,这些因素可能会导致Smart for Life的实际结果、业绩或财务状况与对未来结果、业绩或财务状况的预期大不相同。实际结果可能与前瞻性陈述中讨论的预期大不相同。可能导致实际结果与预期大相径庭的因素包括一般行业考虑因素、监管变化、地方或国家经济状况的变化以及在我们提交给证券交易委员会的文件中包含的“风险因素”中列出的其他风险。

Disclaimer

免责

The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

本新闻稿中提供的信息仅供一般知识使用,并不能替代特定医疗条件下的专业医疗建议或治疗。如果您有任何关于健康状况的问题,请务必咨询您的医生或其他有资质的医疗保健提供者。本信息不用于诊断、治疗、治愈或预防任何疾病。

Investor Relations Contact

投资者关系联系人

Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Cresendo Communications,LLC
电话:(212)671-1021
邮箱:smfl@cresendo-ir.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发